2020 (22 POSTS)

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.

View Abstract

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

View Abstract

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186.

View Abstract

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478.

View Abstract

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.

View Abstract

Lafranconi M, Budinsky R, Corey L, Haws L, Klapacz J, Chappell G, Golden R. Exposure to 1,4-dioxane above the metabolic saturation threshold induces a mitogenic key element in the mouse liver cancer mode of action. Abstract #1505. Society of Toxicology 59th Annual Meeting, Virtual, 2020.

View Abstract

Elbeddini A, Hooda N, Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. Am J Case Rep 21:e924058; doi: 10.12659/AJCR.924058. PMID: 32594093.

View Abstract

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362.

View Abstract

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Jena A, et al. 2020. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ 23(6):581-592; doi: 10.1080/13696998.2020.1730123.

View Abstract

Jackson C, Choi J, Khalafallah AM, Price C, Bettegowda C, Lim M, et al. 2020. A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neuro-Oncol 148(3):419–431; https://doi.org/10.1007/s11060-020-03556-y.

View Abstract

Botros D, Dux H, Price C, Khalafallah AM, Mukherjee D. 2020. Assessing the efficacy of repeat resections in recurrent glioblastoma: A systematic review. Neurosurg Rev 44:1259–1271; https://doi.org/10.1007/s10143-020-01331-1.

View Abstract

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. Budget impact of improving adherence to colorectal cancer screening. Abstract PCN148. ISPOR 2020.

View Abstract

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. The impact of increasing mt-sDNA use among colorectal cancer screeners in a US employer population. Abstract PCN145.  ISPOR 2020.

View Abstract

Bylsma LC, Dean R, Lowe K, Sangare L, Alexander D, Fryzek J. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics. Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.

View Abstract

Franzen A, Borghoff SJ. An adverse outcome pathway for renal tumors in male rats through chemical induction of aa2u-globuline (a2u) nephropathy (a2u-N). Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.

View Abstract

Bylsma LC, Dean R, Lowe K, Sangare L, Alexander D, Fryzek J. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics. Poster for Society of Toxicology 59th Annual Meeting, Virtual, 2020.

View Abstract

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al.  Consequences of increasing mt-sDNA utilization among colorectal cancer screening strategies from a payer perspective. American Society of Preventative Oncology 44th Annual ASPO Conference, 2020.

Menon N, Leslie TF, Frankenfeld CL. 2020. Cancer-related diagnostic and treatment capabilities of hospitals in the context of racial residential segregation. Public Health 182(May):95–101; https://doi.org/10.1016/j.puhe.2020.02.004.

View Abstract

2019 (13 POSTS)

Bylsma LC, Dean R, Lowe K, Sangaré L, Alexander DD, Fryzek JP. 2019. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta‐analysis of patient and study characteristics. Cancer Med 8(12):5800–5809; doi: 10.1002/cam4.2413.

View Abstract

Hooda N, McFarlane T, Pasetka M, DeAngelis C. Chemotherapy-induced nausea and vomiting (CINV) in colorectal cancer (CRC) patients undergoing FOLFOX Chemotherapy: A retrospective chart review comparing two Ontario hospitals. Poster presented at the Canadian Society for Pharmaceutical Sciences Annual Conference, Vancouver, BC, May 2019.